Literature DB >> 31672793

Varying Association of Extended Hours Dialysis with Quality of Life.

Brendan Smyth1,2, Oliver van den Broek-Best3,4, Daqing Hong5,6, Kirsten Howard2, Kris Rogers1,7, Li Zuo8, Nicholas A Gray9,10, Janak R de Zoysa11,12, Christopher T Chan13, Hongli Lin14, Ling Zhang15, Jinsheng Xu16, Alan Cass17, Martin Gallagher1,18, Vlado Perkovic1, Meg Jardine19,18.   

Abstract

BACKGROUND AND OBJECTIVES: Little is known about the effect of changes in dialysis hours on patient-reported outcome measures. We report the effect of doubling dialysis hours on a range of patient-reported outcome measures in a randomized trial, overall and separately for important subgroups. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The A Clinical Trial of IntensiVE Dialysis trial randomized 200 participants to extended or standard weekly hours hemodialysis for 12 months. Patient-reported outcome measures included two health utility scores (EuroQOL-5 Dimensions-3 Level, Short Form-6 Dimension) and their derived quality-adjusted life year estimates, two generic health scores (Short Form-36 Physical Component Summary, Mental Component Summary), and a disease-specific score (Kidney Disease Component Score). Outcomes were assessed as the mean difference from baseline using linear mixed effects models adjusted for time point and baseline score, with interaction terms added for subgroup analyses. Prespecified subgroups were dialysis location (home- versus institution-based), dialysis vintage (≤6 months versus >6 months), region (China versus Australia, New Zealand, Canada), and baseline score (lowest, middle, highest tertile). Multiplicity-adjusted P values (Holm-Bonferroni) were calculated for the main analyses.
RESULTS: Extended dialysis hours was associated with improvement in Short Form-6 Dimension (mean difference, 0.027; 95% confidence interval [95% CI], 0.00 to 0.05; P=0.03) which was not significant after adjustment for multiple comparisons (Padjusted =0.05). There were no significant differences in EuroQOL-5 Dimensions-3 Level health utility (mean difference, 0.036; 95% CI, -0.02 to 0.09; P=0.2; Padjusted =0.2) or in quality-adjusted life years. There were small positive differences in generic and disease-specific quality of life: Physical Component Summary (mean difference, 2.3; 95% CI, 0.6 to 4.1; P=0.01; Padjusted =0.04), Mental Component Summary (mean difference, 2.5; 95% CI, 0.5 to 4.6; P=0.02; Padjusted =0.05) and Kidney Disease Component Score (mean difference, 3.5; 95% CI, 1.5 to 5.5; P=0.001; Padjusted =0.005). The results did not differ among predefined subgroups or by baseline score.
CONCLUSIONS: The effect of extended hours hemodialysis on patient-reported outcome measures reached statistical significance in some but not all measures. Within each measure the effect was consistent across predefined subgroups. The clinical importance of these differences is unclear.
Copyright © 2019 by the American Society of Nephrology.

Entities:  

Keywords:  Australia; Canada; China; New Zealand; chronic hemodialysis; confidence intervals; home hemodialysis; humans; kidney; kidney diseases; patient reported outcome measures; quality of life; quality-adjusted life years; randomized controlled trials; renal dialysis

Mesh:

Year:  2019        PMID: 31672793      PMCID: PMC6895496          DOI: 10.2215/CJN.06800619

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  41 in total

1.  The SF36 as an outcome measure of services for end stage renal failure.

Authors:  J P Wight; L Edwards; J Brazier; S Walters; J N Payne; C B Brown
Journal:  Qual Health Care       Date:  1998-12

Review 2.  Health related quality of life outcome instruments.

Authors:  Gunnar Németh
Journal:  Eur Spine J       Date:  2005-12-01       Impact factor: 3.134

3.  Valuation of the SF-6D Health States Is Feasible, Acceptable, Reliable, and Valid in a Chinese Population.

Authors:  Cindy L K Lam; John Brazier; Sarah M McGhee
Journal:  Value Health       Date:  2008 Mar-Apr       Impact factor: 5.725

4.  Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes.

Authors:  M Tonelli; N Wiebe; G Knoll; A Bello; S Browne; D Jadhav; S Klarenbach; J Gill
Journal:  Am J Transplant       Date:  2011-08-30       Impact factor: 8.086

5.  Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop.

Authors:  Allison Tong; Braden Manns; Brenda Hemmelgarn; David C Wheeler; Nicole Evangelidis; Peter Tugwell; Sally Crowe; Wim Van Biesen; Wolfgang C Winkelmayer; Donal O'Donoghue; Helen Tam-Tham; Jenny I Shen; Jule Pinter; Nicholas Larkins; Sajeda Youssouf; Sreedhar Mandayam; Angela Ju; Jonathan C Craig
Journal:  Am J Kidney Dis       Date:  2016-08-03       Impact factor: 8.860

6.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

7.  Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial.

Authors:  Bruce F Culleton; Michael Walsh; Scott W Klarenbach; Garth Mortis; Narine Scott-Douglas; Robert R Quinn; Marcello Tonelli; Sarah Donnelly; Matthias G Friedrich; Andreas Kumar; Houman Mahallati; Brenda R Hemmelgarn; Braden J Manns
Journal:  JAMA       Date:  2007-09-19       Impact factor: 56.272

8.  Patient quality of life on quotidian hemodialysis.

Authors:  A Paul Heidenheim; Norman Muirhead; Louise Moist; Robert M Lindsay
Journal:  Am J Kidney Dis       Date:  2003-07       Impact factor: 8.860

9.  Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study.

Authors:  Mark Unruh; Robert Benz; Tom Greene; Guofen Yan; Srinivasan Beddhu; Maria DeVita; Johanna T Dwyer; Paul L Kimmel; John W Kusek; Alice Martin; Josephine Rehm-McGillicuddy; Brendan P Teehan; Klemens B Meyer
Journal:  Kidney Int       Date:  2004-07       Impact factor: 10.612

Review 10.  A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments.

Authors:  Melanie Wyld; Rachael Lisa Morton; Andrew Hayen; Kirsten Howard; Angela Claire Webster
Journal:  PLoS Med       Date:  2012-09-11       Impact factor: 11.069

View more
  5 in total

1.  How Extended Hemodialysis Treatment Time Can Affect Patient Quality of Life.

Authors:  Adam S Wilk; Janice P Lea
Journal:  Clin J Am Soc Nephrol       Date:  2019-10-31       Impact factor: 8.237

2.  Patient-centeredness and the Pareto principle: getting at the matter of what matters to our patients.

Authors:  Josephine P Briggs
Journal:  Nephrol Dial Transplant       Date:  2020-10-01       Impact factor: 5.992

3.  The Symptom Monitoring with Feedback Trial (SWIFT): protocol for a registry-based cluster randomised controlled trial in haemodialysis.

Authors:  Lavern Greenham; Paul N Bennett; Kathryn Dansie; Andrea K Viecelli; Shilpanjali Jesudason; Rebecca Mister; Brendan Smyth; Portia Westall; Samuel Herzog; Chris Brown; William Handke; Suetonia C Palmer; Fergus J Caskey; Cecile Couchoud; John Simes; Stephen P McDonald; Rachael L Morton
Journal:  Trials       Date:  2022-05-19       Impact factor: 2.728

Review 4.  A Comparison of Patient-Reported Outcome Measures of Quality of Life By Dialysis Modality in the Treatment of Kidney Failure: A Systematic Review.

Authors:  Brandon Budhram; Alison Sinclair; Paul Komenda; Melissa Severn; Manish M Sood
Journal:  Can J Kidney Health Dis       Date:  2020-10-19

5.  Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis.

Authors:  Melissa Nataatmadja; Rathika Krishnasamy; Li Zuo; Daqing Hong; Brendan Smyth; Min Jun; Janak R de Zoysa; Kirsten Howard; Jing Wang; Chunlai Lu; Zhangsuo Liu; Christopher T Chan; Alan Cass; Vlado Perkovic; Meg Jardine; Nicholas A Gray
Journal:  Kidney Int Rep       Date:  2021-02-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.